MarketsandMarkets

BioGeNe Series 2023

8th - 9th February 2023

Double Tree by Hilton, San Diego - Mission Valley

Third Series of BioGeNe

MarketsandMarkets is here with a platform for pharmaceutical, biotechnology professionals and technology providers to come together at the BioGeNe 2023 Confex on the 8th - 9th February 2023 in San Diego-USA to discuss advancements and solutions to the most critical challenges in the Biomarker, Microbiome and Genome engineering areas.

Tag Line
Biomarker and Companion Diagnostics Immuno-Oncology Cancer Biomarkers Biomarker discovery/ development Translational research Clinical Biomarker Biomarkers in IO and Neurological disorders Imaging Biomarkers Pathology Companion Diagnostics
Tag Line
Next Gen Microbiome and Probiotics Microbiome discovery Department of Biochemistry and Immunology Microbiome science Microbiology Biological Science Gut Biology Human microbiome Drug discovery Therapeutics
Tag Line

Drug discovery businesses have begun to invest in cutting-edge methods for biomarker discovery because of mounting demands related to the success rates of FDA-approved biomarkers and associated diagnostic tests. Speakers are to discuss about Biomarker and Companion Diagnostics and Microbiome and Probiotics. In the past year, the genome editing sector has seen some impressive advancements in the fields of genome writing, base editing, and specific advancements in the treatments using Car-T cells and immunotherapy. Numerous small innovative businesses are present in the market because of the growing emphasis on the development of probiotics products and drugs as well as human microbiome therapies.

The two conferences which are going to be a part of BioGeNe Confex 2023 are, 8th Annual MarketsandMarkets Biomarker and Companion Diagnostics and 5th Annual MarketsandMarkets Next Gen Microbiome and Probiotics .

CO-LOCATED CONFERENCES

8th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference
5th Annual MarketsandMarkets Next Gen Microbiome and Probiotics Conference

WHAT TO EXPECT

  • Commercialization of CDx
  • Proteomics and Genomics based Biomarkers
  • Biomarker Drug Discovery and Assay Development
  • Effective Microbiome Therapeutics in Production
  • Role of human skin microbiome in precision health
  • The increasing pro bacterial beauty industry
  • Business collaborations- Regulations and Investments
  • Novel horizons in biomarker strategies,
  • Liquid biopsy-based disease detection
  • Current Multi Omics analysis
  • Artificial Intelligence and Machine Learning
  • Gene expression Profiling in Precision Medicine
  • Multiplex Companion Diagnostics and Regulatory Guidelines
  • Design of clinical trials in CDx
  • Microbiome as a science and its clinical applications- skin, gut & women’s health
  • Prebiotics, Probiotics and Postbiotics

  • To share and exchange the recent trends and techniques in Personalized Medicine
  • Quality insights and cohesiveness of key issues and obstacles experienced by the healthcare providers while implementing Precision Medicine
  • Discover the different avenues in patient centric care
  • Access wide range of novel applications, innovative research, regulatory and policy development
  • Opportunity for one-on-one networking and extend professional competency with experts ranging from Government, Industry, Technology, Research and Healthcare providers
  • Be a part of the conversations via panel discussion with great lineup of experts

Researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

Biomarker discovery/development, Translational research, Clinical Biomarker, Biomarkers in IO and Neurological disorders, Imaging Biomarkers, Pathology, Companion Diagnostics, Biomarker Imaging, Proteomics Biomarkers, Experimental Medicine, Data Science. Microbiome discovery, Department of Biochemistry and Immunology, Microbiome science, Microbiology, Biological Science, Gut Biology, Human microbiome, Drug discovery, Therapeutics, Immunotherapy

Industry: Pharma/Therapeutic Companies/Start Up’s

CEOs, CMO’s, CSO’s, COO’s, Presidents, Vice Presidents, Directors, Managing Directors, Head of Departments, Executive Leaders, Pharmacists, Oncologists, Immunologists, Geneticists, Principal Scientists, Big Data Scientists, Business Development, Regulatory and Policy Advisors, Diagnostic Laboratory Professionals, Global Leaders.

Departments: Oncology, Personalized medicine, Immunology, Molecular Biology, Genetics and genomic medicine, Molecular Medicine, Pharmacogenomics, Biotechnology

Academics: Universities, Research Institutes, Hospitals

Head of Departments, Professors, Lecturers, Senior Scientists, Researchers, Bioinformaticians

Departments: Oncology, Personalized medicine, Immunology, Molecular Biology, Genetics and genomic medicine, Molecular Medicine, Pharmacogenomics, Biotechnology

CONFERENCE SPEAKERS

ADVISORS

Seth D. Crosby

Seth D. Crosby

Director, Research Collaborations, Washington University School of Medicine

 Julius Goepp

Julius Goepp

CEO, Evimero

Arun K. Bhunia

Arun K. Bhunia

Professor of Food Microbiology, Chair, Interdepartmental Food Science Graduate Program, Department of Food Science, Purdue Institute of Inflammation, Immunology and Infectious Disease

Peter Leighton

Peter Leighton

CEO, ProSperity Bioscience

 Maya Ivanjesku

Maya Ivanjesku

Chief Scientific Officer, Dakota Biotech

SPEAKERS

Tony Grover

Tony Grover

Global Director, Biomarkers and CDx, BD Biosciences Biosciences

Deboleena Sarkar

Deboleena Sarkar

Director Companion Diagnostics Business Development, Qiagen

Scott A. Jackson

Scott A. Jackson

Leader – Complex Microbial Systems Group, NIST - National Institute of Standards and Technology

Leigh A. Frame

Leigh A. Frame

Director, George Washington School of Medicine & Health Sciences

Larry Weiss

Larry Weiss

Chief Executive Officer and Founder, Symbiome

Yug Varma

Yug Varma

CEO, Phi Therapeutics

 Nicole M. Scott

Nicole M. Scott

CEO and Founder, Cybele Microbiome

 Emily Stein

Emily Stein

CEO, Primal Health Inc.

Arun K. Bhunia

Arun K. Bhunia

Professor of Food Microbiology, Chair, Interdepartmental Food Science Graduate Program, Department of Food Science, Purdue Institute of Inflammation, Immunology and Infectious Disease

Peter Leighton

Peter Leighton

CEO, ProSperity Bioscience

John Rossi

John Rossi

Vice President, Head, Translational Medicine, , Syncopation Lifesciences

Scott J. Bornheimer

Scott J. Bornheimer

Associate Director, Medical & Scientific Affairs, BD Biosciences

Heather Cohen

Heather Cohen

Director, Translational Sciences, Bicycle Therapeutics

Rakesh Dixit

Rakesh Dixit

CEO, Bionavigen

Majid Ghoddusi

Majid Ghoddusi

Senior Director, Clinical Biomarkers, Poseida Therapeutics

Desiree Schenk

Desiree Schenk

Principal Scientist, Gritstone Oncology

Yingpeng Zhan

Yingpeng Zhan

Scientist, Sorrento Therapeutics

Craig Thomson

Craig Thomson

Partner, HGF IP Limited

Ian Pike

Ian Pike

Chief Scientific Officer, Proteome Sciences PLC

Amy Wehn

Amy Wehn

Director, Companion Diagnostics, Merck

 Julius Goepp

Julius Goepp

CEO, Evimero

Katrine L. Whiteson

Katrine L. Whiteson

Associate Professor, Molecular Biology and Biochemistry School of Biological Sciences,, University of California Irvine

Andrea Azcarate-Peril

Andrea Azcarate-Peril

Associate Professor of Medicine, Director, UNC Microbiome Core, School of Medicine, University of North Carolina at Chapel Hill

Juliana Durack

Juliana Durack

VP of Research and Product Development, Symbiome

Jan Struckmann Poulsen

Jan Struckmann Poulsen

PhD student | Department of Chemistry and Bioscience, Aalborg University

Ace Hatch

Ace Hatch

Senior Biomarker Scientist, Owlstone Medical

Dana Buckman

Dana Buckman

CEO, BioForm Solutions

Robert H. Schiestl

Robert H. Schiestl

Professor emeritus of Pathology and Environmental Health Sciences and Radiation Oncology, UCLA Schools of Medicine and Public Health

Seth D. Crosby

Seth D. Crosby

Director, Research Collaborations, Washington University School of Medicine

Robert L Hettich

Robert L Hettich

Distinguished Research Staff Member, Oak Ridge National Laboratory

Suparna Mitra

Suparna Mitra

University Academic fellow (Bioinformatics lead), University of Leeds

Ravichandra Vemuri

Ravichandra Vemuri

Microbiome Scientist at Department of Pathology, Wake Forest School of Medicine, NC.

Manish Kohli

Manish Kohli

Professor, Huntsman Cancer Institute, University of Utah

Michael Milburn

Michael Milburn

President, CEO, GeneCentric Therapeutics

George Pell

George Pell

CEO and Founder, Thirty-Six

Shannon Muir

Shannon Muir

Co-director of the California Initiative to Advance Precision Medicine in the California Governor’s Office of Planning and Research,

Mason Israel

Mason Israel

Regional Medical Affairs Director, Mirati Therapeutics

Ginette Serrero

Ginette Serrero

Chief Executive Officer, A&G Pharmaceutical, Inc. | Precision Antibody

Hideki Furuya

Hideki Furuya

Assistant Professor, Cedars-Sinai Medical Center

Maria Wang

Maria Wang

Associate Director, Bristol-Myers Squibb

ENQUIRE NOW

SPONSORS

PARTNERS

LOCATION

Venue

Double Tree by Hilton, San Diego - Mission Valley

PAST EVENT GALLERY